Idarubicin is a medication used in this trial to treat acute myeloid leukemia (AML). It is part of a group of drugs known as anthracyclines, which work by interfering with the DNA inside cancer cells, preventing them from growing and multiplying. In this study, idarubicin is being compared to another similar drug to see which one is more effective in helping patients live longer.

Daunorubicin is another medication used in the trial for treating AML. Like idarubicin, it belongs to the anthracycline family and works by disrupting the DNA of cancer cells, stopping their growth. The trial aims to determine whether daunorubicin or idarubicin is better at improving patient survival rates.

Cytarabine is a chemotherapy drug used in this study to help eliminate cancer cells in patients with AML. It works by interfering with the DNA of the cancer cells, which stops them from dividing and growing. The trial is comparing different doses of cytarabine to find out which dose is more effective in treating the disease.

Mycophenolic Acid is used in the trial as a standard treatment to prevent a condition called graft versus host disease (GvHD) in patients who have received a stem cell transplant. GvHD can occur when the transplanted cells attack the patient’s own body. Mycophenolic acid helps to suppress the immune system, reducing the risk of this condition.

Acute myeloid leukemia – Acute myeloid leukemia is a type of cancer that starts in the blood-forming cells of the bone marrow. It progresses rapidly, leading to the accumulation of immature white blood cells called myeloblasts. These cells crowd out normal blood cells, causing symptoms like fatigue, frequent infections, and easy bruising or bleeding. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The rapid progression requires prompt medical attention to manage the symptoms and complications.